archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL opens $4.8m workplace childcare centre
    15 years experience and over 50 services throughout Melbourne the Centre will nurture growing young minds while empowering families to be involved in their children s learning For Dr Brian McNamee Chief Executive Officer and Managing Director of CSL Limited the Thinking Kids Children s Centre represents a serious investment in the future of CSL The decision to provide a work based childcare service will assist us to attract and retain talented employees and to foster a positive and inclusive workplace explains Dr McNamee The concept of a work based childcare service was initiated five years ago when CSL identified a need amongst their 1 800 local employees to support them to return to work after having a child A 2006 survey of staff found that 63 per cent of the 107 employees who had taken maternity leave in the previous five years were no longer with CSL This was a concerning trend for CSL because females makes up a significant proportion of employees professional staff and future talent Talent is always in limited supply and CSL cannot afford to lose well educated and trained employees who want to work but whose choice is impacted by a lack of childcare stated Dr McNamee With a significant number of our employees not coming back to work after maternity leave and growing evidence about the benefits of workplace childcare we had good reason to provide a childcare service for our employees which may enable them to return to work Building the Thinking Kids Children s Centre made good business sense but it also demonstrates that CSL lives and breathes our commitment to diversity and equal opportunity We believe the Centre will provide social and financial benefits for our business employees and community The Thinking Kids Children s Centre builds upon CSL s

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927196164/prdetail.htm (2014-01-05)
    Open archived version from archive


  • CSL Limited today announced Full Year Results for 2010/11.
    2011 down 112 million or 11 when compared to the prior comparable period This result included an unfavourable foreign exchange impact of 116 million On a constant currency 1 basis operational net profit after tax grew 14 after excluding a one off contribution from the sale of pandemic influenza vaccine H1N1 in the prior period Download this release CSL Full Year results announcement for 20010 11 0 1 Mb Additional

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927066660/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Announces Changes to the Board
    and 1980s He returned to Australia to become Executive Director of the Garvan Institute of Medical Research a position that he will be stepping down from at the end of 2011 and developed it as one of Australia s premier Medical Institutes Professor Shine was formerly Chairman of the National Health and Medical Research Council and a member of the Prime Minister s Science Engineering and Innovation Council In November 2010 he was awarded the Prime Minister s Prize for Science Professor Shine has extensive Board and governance experience and is well placed to guide CSL s strategic future Miss Alexander has been a Director of the Company since July 1991 and has been Chairman since October 2006 Prior to becoming the Chairman of CSL she was the Chairman of CSL s Audit and Risk Committee Miss Alexander played a key role in CSL s highly successful public listing and has been a constant champion of the Company s international expansion plans Her financial leadership and strong commitment to corporate governance has helped transform CSL from a domestic biologics manufacturer to a global speciality biopharmaceutical company Mr Simpson has been a director of the Company since September 2006 and has served as a member and Chairman of both the Company s Audit and Risk Management Committee and the Human Resources and Remuneration Committee CSL s Chairman elect Professor John Shine said I am very proud to be taking over as Chairman from Elizabeth after the Annual General Meeting She has made an extraordinary contribution to CSL over many years and leaves the Company well positioned for the future I would also like to recognise and thank David for his commitment and contribution during his time as a Director CSL today also announced that Mr Bruce Brook has been appointed a

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255927066426/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL subsidiary donates von Willebrand Factor / Factor VIII to World Federation of Hemophilia
    of VWD medication via WFH s Global Alliance for Progress program as part of its 3 year commitment to the organization King of Prussia PA and Montreal Canada 18 07 2011 CSL Behring has donated more than 1 million international units IU of von Willebrand factor VWF Factor VIII FVIII replacement medication to patients through the World Federation of Hemophilia WFH The donation supports WFH s progress in improving the

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255926857179/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Biotherapies Statement on FDA Warning Letter for GMP issues at Australian Influenza Vaccine Facility
    CSL Biotherapies a division of CSL Limited The FDA regulates the manufacture marketing and distribution of CSL Biotherapies influenza vaccine Afluria in the US market The Warning Letter relates to the FDA s most recent annual inspection of CSL Biotherapies influenza vaccine manufacturing facilities processes and procedures at the Parkville Australia site in March 2011 The Letter is available on the FDA website At the completion of the March inspection the FDA issued CSL Biotherapies with a list of observed deviations from current Good Manufacturing Practice GMP CSL Biotherapies submitted a written response to the FDA to address the observations including details of corrective steps that had already been undertaken as well as further actions underway The Warning Letter states that CSL Biotherapies response to the March inspectional observations did not provide sufficient detail for the FDA to fully assess the adequacy of CSL Biotherapies corrective actions The Letter lists a number of significant items that require prompt attention These primarily relate to the methodology used by CSL Biotherapies to document and manage processes and investigations at its Parkville facility CSL Biotherapies is committed to the highest standards of compliance in our quality systems and we are taking the Warning Letter very seriously Our technical team is in the process of preparing more substantive detail about our corrective actions to meet the FDA s requirements said Dr Jeff Davies Executive Vice President CSL Biotherapies We will work diligently with the FDA to resolve these GMP issues as quickly as possible while continuing to fulfil our commitments to public health programs in Australia and internationally said Dr Davies Background CSL Biotherapies is a division of CSL Limited ASX CSL In fiscal 2010 CSL Limited reported total revenues of 4 6 billion In the same period CSL Biotherapies total worldwide sales of

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255926584811/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL welcomes historic pandemic agreement
    greater global collaboration between public and private stakeholders in preparing the world for possible future influenza pandemics With the continuing risk of an influenza pandemic with potentially devastating impacts the adoption of this framework is a wonderful achievement for public health We congratulate the WHO and member country governments including Australia and look forward to continuing to work with all parties to develop an effective implementation plan said Dr Brian McNamee CEO and Managing Director of CSL Limited The Framework establishes the principles by which international agencies governments and biopharmaceutical manufacturers will collectively contribute to strengthening global pandemic preparedness building on key learnings from the 2009 H1N1 Pandemic and utilising the significant investments and contributions that industry and other stakeholders already make We were pleased to meet our long standing commitments to Australia during the H1N1 pandemic and to make vaccine available in many other countries including some of the poorest As part of the new Framework we will work towards committing at least 10 of our real time vaccine output to the WHO to further improve access in developing countries said Dr McNamee CSL operates the largest influenza vaccine manufacturing facility in the Southern Hemisphere The Company plays a significant role in pandemic preparedness and response in Australia and is able to leverage its capabilities and capacity to quickly produce pandemic vaccine for both local and global markets CSL was one of the first companies in the world to develop the H1N1 pandemic vaccine conduct clinical trials and make vaccine available for public use Pandemics can have devastating economic and social consequences particularly in developing countries which are more vulnerable In addition to our vaccine pledge CSL will also look for unique ways to directly assist developing countries with their pandemic preparedness activities said Dr McNamee Under the Framework

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255926424260/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Recombinant Technologies
    Australia 20 05 2011 CSL Limited ASX CSL subsidiary CSL Behring today issued a press release regarding advances that it is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with haemophilia A and B This will be the topic of an oral presentation at an international medical congress on 22 May 2011 A copy of this press release is available on the CSL Behring

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255926420967/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    are consistent with the 2011 product information which states that children under five years of age should not receive Fluvax vaccine In addition ATAGI has recommended that children aged five to less than 10 years of age should receive an alternative influenza vaccine if available CSL fully supports the ATAGI recommendations and continues to work closely with health authorities to mitigate the risk of further febrile events in children following the use of our seasonal influenza vaccine said Dr Alan Paul Medical Director at CSL Biotherapies In addition to ongoing post marketing safety surveillance CSL is collaborating with a number of paediatric research centres to undertake active surveillance of influenza vaccine use in 600 children aged five to 18 years said Dr Paul The ATAGI recommendations support the use of Fluvax vaccine in people aged ten years and over Ongoing monitoring of CSL s influenza vaccine in both Southern and Northern Hemisphere countries has not identified any safety signals following its use in this age group Safety is our highest priority at CSL and we continue to work diligently with regulators and global experts to resolve the cause of the increased reports of febrile events associated with our 2010 influenza

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255926020733/prdetail.htm (2014-01-05)
    Open archived version from archive